Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference

Core Viewpoint - Olema Pharmaceuticals, Inc. is focused on developing targeted therapies for breast cancer and will present at the TD Cowen 46 Annual Health Care Conference on March 3, 2026 [1] Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company dedicated to improving outcomes for breast cancer patients and is advancing a pipeline of novel therapies [3] - The lead product candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, currently in two Phase 3 clinical trials [3] - Olema is also developing OP-3136, a potent KAT6 inhibitor, which is in a Phase 1 clinical study [3] - The company is headquartered in San Francisco with operations in Cambridge, Massachusetts [3]